Chris Green: To ask the Secretary of State for Health and Social Care, how many participants were recruited into NIHR supported phase 3 trials for (a) dementia, (b) cancer, (c) stroke and (d) coronary heart disease over the last 10 years.
Chris Green: To ask the Secretary of State for Business, Energy and Industrial Strategy, when the Global Britain Investment Fund will open for investment for new medicines manufacturing; and what steps he is taking to ensure that the fund supports innovative, smaller biotechnology companies.
Chris Green: To ask the Secretary of State for Health and Social Care, what progress he has made on the implementation of the proposals in his Department's policy paper, Saving and Improving Lives: The Future of UK Clinical Research Delivery; and what funding has been allocated to the longer-term implementation of those proposals.
Chris Green: To ask the Secretary of State for Health and Social Care, if he will take steps to implement the strategy set out in his Department's policy paper, Saving and Improving Lives: The Future of UK Clinical Research Delivery, to ensure the attractiveness of the UK for early-stage clinical trials.
Chris Green: To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 11 January 2022 to Question 96909, on Cancer: Drugs, how many breast cancer drugs are being assessed through the Project Orbis licensing route.
Chris Green: To ask the Secretary of State for Health and Social Care, what assessment he has made of the (a) technology capability and (b) workforce expertise in each of the genomic laboratory hubs; and if he will publish that assessment.
Chris Green: I welcome my right hon. Friend’s statement. He made several references to conditions of employment and he finished by asking regulators, “to urgently review current guidance to registrants on vaccinations”. What will he do to ensure that that does not become a compulsion for vaccinations by other means?
Chris Green: To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 11 January 2022 to Question 96910 on National Institute for Health and Care Excellence, how many oncology technical appraisals have been rescheduled in the last six months directly as a result of NICE operational challenges; and what the average time taken has been to reschedule those appraisals.
Chris Green: To ask the Chancellor of the Exchequer, when he plans to publish his Department's response to its consultation entitled R&D Tax Reliefs.
Chris Green: To ask the Chancellor of the Exchequer, whether he has made an assessment of the potential effect on research and development tax relief of territoriality restrictions having been in place for each of the last five years, by sector.
Chris Green: To ask the Chancellor of the Exchequer, what discussions he has had with the life sciences sector to discuss the issue of territoriality for R&D tax relief.
Chris Green: To ask the Secretary of State for Business, Energy and Industrial Strategy, whether he has made an assessment of the potential effect of the UK's regulatory framework on the number of life sciences companies that deem it necessary to conduct clinical trials outside of the UK; and whether he has plans to make exceptions under the existing framework to enable more UK-based life science...
Chris Green: To ask the Secretary of State for Health and Social Care, what discussions his Department has had with NICE on their (a) current and (b) future capacity to deliver final draft guidance on medicines within three months of regulatory approval by the MHRA.
Chris Green: To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of the MHRA joining the Project Orbis scheme in January 2021 on the speed of patient access to new oncology medicines.
Chris Green: To ask the Secretary of State for Health and Social Care, what assessment he has made of the impact of operational challenges faced by NICE on its ability to deliver timely patient access to new medicines.
Chris Green: To ask the Secretary of State for Health and Social Care, if he will publish data on the number of covid-19 (a) tests delivered and (b) patients referred to each genomic laboratory hub in the 12 months for which that data is available.
Chris Green: To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the variation in survival rates for patients receiving dialysis at home compared to those receiving it in-centre.
Chris Green: To ask the Secretary of State for Health and Social Care, how many patients from lower socio-economic backgrounds have received kidney dialysis treatment at home in the last five years compared to patients from higher socio-economic backgrounds.
Chris Green: To ask the Secretary of State for Health and Social Care, what assessment he has made of the variation in access to home kidney dialysis for patients from Black, Asian or minority ethnicity backgrounds compared to patients from other backgrounds; and what assessment he has made of the reasons for that variation.
Chris Green: To ask the Secretary of State for Health and Social Care, if he will ask NICE to undertake an analysis of whether its proposed new methods for assessing medicines will improve the access of NHS patients to new treatment in comparison to other developed countries in Europe.